Apar Kishor Ganti (@aparganti) 's Twitter Profile
Apar Kishor Ganti

@aparganti

ID: 1367279102017871873

calendar_today04-03-2021 01:02:06

1,1K Tweet

319 Followers

244 Following

Lynn Schuchter (@lynn_schuchter) 's Twitter Profile Photo

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO ASCO Her legacy touches so many domains. Congrats to Dr. Jamie Von Roenn ASCO Special Award: will now be the Jamie Von Roenn Excellence in Teaching Award. “ There are two ways of spreading light: to be the candle or the mirror that reflects it” E Wharton. You my friend are both.

<a href="/tomleblancMD/">Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO</a> <a href="/ASCO/">ASCO</a> Her legacy touches so many domains. Congrats to Dr. Jamie Von Roenn <a href="/ASCO/">ASCO</a> Special Award: will now be the Jamie Von Roenn Excellence in Teaching Award. “ There are two ways of spreading light: to be the candle or the mirror that reflects it” E Wharton. You my friend are both.
Research @ UNMC (@unmc_research) 's Twitter Profile Photo

A research team in the UNMC Department of Genetics, Cell Biology and Anatomy has been awarded a five-year, $1.45 million grant through NIH to expand the pipeline of data scientists in bioinformatics. Learn more ⬇️⬇️⬇️ unmc.edu/newsroom/2024/…

UNMC Geriatrics and Palliative Care (@unmc_geripalli) 's Twitter Profile Photo

Congratulations to our own Dr. Thuy Koll for being awarded the Clinical Research Award: This award is intended to recognize junior or mid-level faculty for excellence in a clinical research program. Thanks for all you do Dr Koll

Congratulations to our own Dr. Thuy Koll for being awarded the Clinical Research Award: This award is intended to recognize junior or mid-level faculty for excellence in a clinical research program. Thanks for all you do Dr Koll
DAVA Oncology (@davaonc) 's Twitter Profile Photo

Aloha! The wait is almost over⏰Follow us for updates and highlights from DAVA's 2024 Summit on Thoracic Malignancies! Register for the free virtual program: forms.gle/xfGC2B9LgLm3n1….

Aloha! The wait is almost over⏰Follow us for updates and highlights from DAVA's 2024 Summit on Thoracic Malignancies! Register for the free virtual program: forms.gle/xfGC2B9LgLm3n1….
Jeffrey peppercorn MD (@ethicsdoctorp) 's Twitter Profile Photo

JCO Oncology Practice is proud to announce our 2023 Impact Factor of 4.7! 🥳 🙏 Thank you to our dedicated authors, reviewers, and readers! ➡️ Submit your impactful research and commentary on cancer care delivery and policy today!

JCO Oncology Practice is proud to announce our 2023 Impact Factor of 4.7!  🥳

🙏 Thank you to our dedicated authors, reviewers, and readers!  

➡️ Submit your impactful research and commentary on cancer care delivery and policy today!
Patrick C. Ma, MD (@patrickcma1) 's Twitter Profile Photo

Thank you DAVA Oncology and Dr. Vinay Jain for the invitation to join this awesome faculty group in the DAVA Global Summit for Thoracic Malignancies, Kona Hawaii. As Dr. Salgia says always: We truly have come a Lung 🫁 way!!! #DAVALung Penn State Health

Thank you <a href="/DAVAOnc/">DAVA Oncology</a> and Dr. Vinay Jain for the invitation to join this awesome faculty group in the DAVA Global Summit for Thoracic Malignancies, Kona Hawaii. As Dr. Salgia says always: We truly have come a Lung 🫁 way!!! #DAVALung <a href="/PennStHershey/">Penn State Health</a>
Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) 's Twitter Profile Photo

I am pleased to join Oncotarget Oncotarget Journal as an Editor-in-Chief this June, 2024. This is a great journal that was started in 2010. The journal has published impactful research over the years by leaders in the field. The journal is indexed in PubMed, PMC, and MEDLINE and

I am pleased to join <a href="/Oncotarget/">Oncotarget</a> <a href="/OncotargetJrnl/">Oncotarget Journal</a> as an Editor-in-Chief this June, 2024.

This is a great journal that was started in 2010. The journal has published impactful research over the years by leaders in the field. The journal is indexed in PubMed, PMC, and MEDLINE and
JAMA Oncology (@jamaonc) 's Twitter Profile Photo

In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with high-risk biochemically recurrent prostate cancer following prostatectomy. ja.ma/3SXsCLu

In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with high-risk biochemically recurrent prostate cancer following prostatectomy. ja.ma/3SXsCLu